Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has confirmed that the Seoul Central District Prosecutors’ Office filed an appeal against the first-instance acquittal regarding embezzlement and malfeasance charges.
📊 [Key Disclosure Details & Financial Figures]
- Incident Details: Confirmation of an appeal filed by the Seoul Central District Prosecutors’ Office against the first-instance acquittal on embezzlement and malfeasance charges
- Alleged Amount Involved: KRW 4,712,615,000
- Total Equity: KRW 8,984,474,395,157 (Based on consolidated total equity at the end of 2022)
- Ratio to Total Equity: 0.05%
- Occurrence Date & Confirmation Date: February 20, 2024
- Future Countermeasures: The company plans to monitor progress in subsequent legal proceedings
- Other Remarks:
- The appealed matter corresponds to the indictment originally filed on October 12, 2020
- Subsequent developments or finalized facts will be disclosed in future filings
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Legal Proceedings Following Prosecution Appeal
This disclosure reports that legal proceedings remain ongoing as the Seoul Central District Prosecutors’ Office has appealed the first-instance acquittal decision regarding embezzlement and malfeasance charges. Tracking the progression and final judgment of these judicial proceedings is essential to verify the ultimate resolution of legal uncertainty. Investors can confirm future developments through subsequent disclosures or periodic reports.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
